Package Insert: Information for the Patient
Paxtibi 25 mg Coated Tablets
nortriptilina hidrocloruro
Read this entire package insert carefully before taking this medicine, as it contains important information for you.
Paxtibi contains the active ingredient nortriptyline.
Nortriptyline belongs to a group of medications known as tricyclic antidepressants, used for the treatment of major depressive episode in adults.
(MAOIs - other medications used for depression or selegiline (used to treat Parkinson's disease) or have taken them in the last 14 days: if you have taken any of these medications, you must wait 14 days before starting to take this medication.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication.
Thoughts of suicide and worsening of depression
If you are depressed and/or have anxiety disorders, it is possible that you may sometimes think about harming yourself or taking your life. These types of thoughts may increase when you first start taking antidepressants, as all these medications take time to work, usually two weeks, but sometimes longer.
You may be more likely to have these types of thoughts:
If you have thoughts of harming yourself or taking your life, contact your doctor or go to a hospital immediately.
It may be helpful to tell a family member or close friend that you are depressed and ask them to read this leaflet. You can ask them to tell you if they think your depression or anxiety is getting worse or if they are concerned about changes in your behavior.
Inform your doctor if you have or have had any medical problems, especially
Some patients with manic-depressive disorders may go through a manic phase. It is characterized by unusual and rapidly changing thoughts, excessive joy and excessive physical activity. In these cases, it is essential to consult your doctor.
Interval QT prolongado
A heart problem called "interval QT prolongado" (which appears on an electrocardiogram [ECG]) and heart rhythm disorders (irregular heartbeat) have been reported with nortriptyline. Inform your doctor if:
If you are taking antidepressants such as selective serotonin reuptake inhibitors (SSRIs), your doctor may consider changing your medication dose (see also section 2 "Taking Paxtibi with other medications" and section 3).
Children and adolescents
Do not administer this medication to children and adolescents under 18 years old for these treatments as the safety and efficacy have not been established in this age group.
Older adults
The dosage should be reduced in the elderly. Older adults have a higher probability of experiencing certain adverse effects such as dizziness when standing due to low blood pressure (see also section 4 "Possible side effects").
Other medications and Paxtibi
Inform your doctor or pharmacist if you are taking, have taken recently or may need to take any other medication. Some medications may affect the functioning of other medications and this can sometimes cause severe side effects.
You should be especially careful if you are taking any of the following medications: monoamine oxidase inhibitors (MAOIs) such as moclobemide (for the treatment of depression) or selegiline (used to treat Parkinson's disease). These medications should not be taken at the same time as nortriptyline (see section 2 "Do not take Paxtibi").
You should also inform your doctor if you are taking or have taken recently medications that may affect heart rhythm such as, for example.medications for irregular heartbeats (e.g. quinidine and sotalol)
Taking Paxtibi with alcohol
Do not drink alcohol during treatment with this medication, as it may increase its sedative effect.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Nortriptyline is not recommended during pregnancy unless your doctor considers it clearly necessary and only after careful consideration of the benefit and risk. If you have taken this medication during the last part of pregnancy, the newborn may experience withdrawal symptoms such as irritability, increased muscle tension, tremors, irregular breathing, poor sucking, loud crying, urinary retention and constipation.
Your doctor will advise you if you should start/continue/stop breastfeeding or interrupt the use of this medication, taking into account the benefit of breastfeeding for the baby and the benefit of treatment for you.
Driving and operating machinery
This medication may cause drowsiness and dizziness, especially at the beginning of treatment. Do not drive or work with tools or machinery until you know how the treatment with nortriptyline affects you.
Paxtibi contains lactose and sunset yellow S
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with him before taking this medication.
This medication contains sunset yellow S (E110, azoic dye).This medication may cause allergic reactions.
Adults
The daily dose for adults is 25 mg, 3 or 4 times a day, starting with a low dose and adjusting the dose. It can be administered once a day, usually at night, or 3 or 4 times a day.
It may take between 2 and 4 weeks to achieve a response. Doses above 150 mg per day are not recommended.
Older adults
The dosage for elderly patients is 25 to 50 mg per day in divided doses.
Treatment should be initiated with a low dose (10-20 mg per day) and increased as needed to a maximum dose of 50 mg.
If it is necessary to increase the dose in an elderly patient, the ECG should be checked and plasma nortriptyline levels monitored.
Pediatric population
Do not administer this medication to children and adolescents under 18 years of age for these treatments, as the safety and efficacy have not been established in this age group.
Liver and kidney insufficiency
It is recommended to reduce the dose in cases of liver or kidney insufficiency, as nortriptyline is extensively metabolized in the liver and primarily eliminated through the kidneys.
How to take Paxtibi
The tablets should be taken with water.
Treatment duration
Do not change the medication dose or interrupt treatment without consulting your doctor first.Continue taking this medication for as long as your doctor recommends.
The underlying disease may persist for a long time. If you stop treatment too soon, symptoms may reappear.
It is recommended to continue treatment for at least 6 months after feeling better.
If you take more Paxtibi than you should
In case of overdose or accidental ingestion, consult your doctor, pharmacist, or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you accidentally take an extra Paxtibi tablet, you may experience or worsen side effects such as drowsiness, dry mouth, dizziness, or nausea.
The symptoms of overdose may include:
The treatment of overdose should be done with general measures, gastric lavage, and assisted respiration.
If you forget to take Paxtibi
Take the next dose at the usual time. Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Paxtibi
Your doctor will decide when and how to interrupt treatment to avoid any unpleasant symptoms that may occur if treatment is stopped abruptly (e.g., headache, feeling of discomfort, insomnia, and irritability).
Therefore, nortriptyline treatment should not be stopped abruptly. The dose should be gradually reduced over a week or more.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
If you notice any of the following symptoms, you should see your doctor immediately:
Prolonged QT interval heart problem (which can be seen on your electrocardiogram).Common side effect, may affect up to 1 in 10 people
Rare side effects, may affect up to 1 in 1,000 people).
Very rare side effect, may affect up to 1 in 10,000 people).
You should have an eye examination immediately before you can continue treatment with this medicine. These symptoms may be a sign of acute glaucoma (Very rare side effect, may affect up to 1 in 10,000 people).
The following side effects have been reported in the following frequencies:
Very common: may affect more than 1 in 10 peoplepeople
Common: may affect up to 1 in 10 peoplepeople
Uncommon: may affect up to 1 in 100 peoplepeople
Rare: may affect up to 1 in 1,000 peoplepeople
Very rare: may affect up to 1 in 10,000 people
Frequency not known (cannot be estimated from available data)
A higher risk of bone fractures has been observed in patients treated with this type of medication.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use: www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
This medication does not require special storage conditions.
Do not usethis medicationafter the expiration date that appears onthe packagingafter CAD.
Do not dispose of medications through drains or trash. Dispose of packaging and medications you no longer need at the SIGREpoint at the pharmacy. If in doubt, ask your pharmacist how to dispose of packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Paxtibi
Each tablet contains 25 mg of nortriptyline hydrochloride.
Appearance of the product and content of the container
Paxtibi 25 mg coated tablets are round, orange, convex, coated with transparent film.
The tablets are presented in aluminum/PVC blister packs of 25 coated tablets.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
Teva B.V.
Swensweg 5, 2031 GA Haarlem
Netherlands
You can request more information about this medication by contacting the local representative of the holder of the marketing authorization:
Biowise Pharmaceuticals
c/Teixidors nº 22, Polígono industrial Can Robiols
07141 Marratxi (Balearic Islands)
Spain
Responsible for manufacturing:
LILLY, S.A.
Avda. de la Industria, 30
Alcobendas (Madrid) 28108
Spain
or
TOLL MANUFACTURING SERVICES, S.L.
Aragoneses, 2
Alcobendas (Madrid) 28108
Spain
Last review date of this leaflet: August 2024
The detailed information about this medication is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.